CClinicalTrials.gg
CompletedNCT03434834Updated Apr 6, 2021Results posted

OCT Pilot in Esophagus

An interventional study of optical coherence tomography in Barrett Esophagus, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-04-06.

Sponsored by Duke University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a pilot study to test a newly developed optical coherence tomography (OCT) device to determine 1) whether adequate tissue contact can be attained to acquire high quality images, and 2) to identify if these images can discern whether the imaged tissue is squamous or Barrett's Esophagus (BE) epithelium.

02

Conditions studied

  • Barrett Esophagus

Browse trials for

03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Presenting to University of North Carolina (UNC) for routine care upper endoscopy
  2. Meet one of the following criteria:

    1. Presenting to UNC for upper endoscopy of GI conditions without esophageal symptomology for with no history of gastroesophageal reflux disease (GERD) or other esophageal condition affecting the epithelium (asymptomatic controls), OR,
    2. History of dysplastic or non-dysplastic Barrett's Esophagus with prague criteria C1+ or M3+
  3. Aged 18 to 80
  4. Able to read, comprehend, and understand the informed consent document.

Exclusion criteria

Exclusion Criteria:

  1. Prior esophageal surgery (uncomplicated nissen fundoplication OK)
  2. Pregnant women
  3. Unable to provide written informed consent
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    OCT of esophagus

    optical coherence tomography of esophagus

    Device: optical coherence tomography

Interventions

  • Deviceoptical coherence tomography

    OCT measurements of 5 locations in the esophagus

05

What researchers measure

Primary outcomes

  1. Percentage of Imaged Sites Correctly Categorized as Squamous Mucosa

    Percentage of imaged sites correctly categorized by OCT as squamous mucosa when compared to endoscopy.

    Time frame: at baseline

  2. Percentage of Imaged Sites Correctly Categorized as Barrett's Mucosa

    Percentage of images site correctly categorized by OCT as Barrett's mucosa when compared to endoscopy.

    Time frame: at baseline

Secondary outcomes

  1. Percentage of Imaged Sites With Adequate Tissue Contact to Acquire a High Quality Image

    Percentage of imaged sites that achieved adequate tissue contact to acquire high quality OCT images.

    Time frame: at baseline

06

Results

Posted Apr 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneOCT of Esophagus
Started53
Completed37
Not completed16
Withdrew: Unable to swallow oct probe16

Outcome measures

PrimaryPercentage of Imaged Sites Correctly Categorized as Squamous Mucosa

Percentage of imaged sites correctly categorized by OCT as squamous mucosa when compared to endoscopy.

Time frame:
at baseline
Reported as:
Number · percentage of imaged sites
Percentage of Imaged Sites Correctly Categorized as Squamous Mucosa
percentage of imaged sitesOCT of Esophagus
Percentage of Imaged Sites Correctly Categorized as Squamous Mucosa93.1
PrimaryPercentage of Imaged Sites Correctly Categorized as Barrett's Mucosa

Percentage of images site correctly categorized by OCT as Barrett's mucosa when compared to endoscopy.

Time frame:
at baseline
Reported as:
Number · percentage of imaged sites
Percentage of Imaged Sites Correctly Categorized as Barrett's Mucosa
percentage of imaged sitesOCT of Esophagus
Percentage of Imaged Sites Correctly Categorized as Barrett's Mucosa84.6
SecondaryPercentage of Imaged Sites With Adequate Tissue Contact to Acquire a High Quality Image

Percentage of imaged sites that achieved adequate tissue contact to acquire high quality OCT images.

Time frame:
at baseline
Reported as:
Number · percentage of imaged sites
Percentage of Imaged Sites With Adequate Tissue Contact to Acquire a High Quality Image
percentage of imaged sitesOCT of Esophagus
Percentage of Imaged Sites With Adequate Tissue Contact to Acquire a High Quality Image80.5

Adverse events

Collected over 1 week. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OCT of Esophagus0/53 (0%)0/53 (0%)8/53 (15.1%)
Most frequent other events
Most frequent other events
EventOCT of Esophagus
sore throatSurgical and medical procedures4/53
bloatingSurgical and medical procedures1/53
nausea / vomitingSurgical and medical procedures1/53
epigastric painSurgical and medical procedures1/53
esophageal painSurgical and medical procedures1/53

Baseline characteristics

Age, Continuous
Age, Continuous(years)OCT of Esophagus
Mean66.3 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)OCT of Esophagus
Female5
Male48
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OCT of Esophagus
Hispanic or Latino0
Not Hispanic or Latino53
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OCT of Esophagus
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White53
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)OCT of Esophagus
United States53
Stage of Barrett's Esophagus
Stage of Barrett's Esophagus(Participants)OCT of Esophagus
non-dysplastic Barrett's Esophagus8
Barrett's Esophagus with low grade dysplasia24
Barrett's Esophagus with high grade dysplasia21
07

Study locations

1 site
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
08

References and documents

Study documents

  • Informed consent form · Jan 9, 2018
  • Protocol and statistical analysis plan · Apr 14, 2020

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03434834
Lead sponsor
Duke University
Collaborators
University of North Carolina, Chapel Hill, National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Feb 15, 2018
Start date
Sep 25, 2018
Primary completion
Feb 25, 2020
Completion
Mar 25, 2020
Results posted
Apr 6, 2021
Last update
Apr 6, 2021

Study contacts

Adam Wax, Ph.D.
principal investigator · Professor

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion